Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients

Atherosclerosis

Volumn 190, Issue 1, 2007, Pages 1-9

  Wakkee, M ^a   Thio, H B ^a   Prens, E P ^a   Sijbrands, E J G ^a   Neumann, H A M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Atherogenesis; Cardiovascular risk; Inflammation; Psoriasis; Statins

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; DITHRANOL; ENDOTHELIN 1; ETRETIN; FUMARIC ACID ETHYL ESTER; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1; MALONALDEHYDE; METHOTREXATE; METHOXSALEN; PROSTAGLANDIN SYNTHASE; RETINOID; TAR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VITAMIN D DERIVATIVE;

BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHEILITIS; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; DYSLIPIDEMIA; FLUSHING; GASTROINTESTINAL SYMPTOM; GENETICS; HAIR LOSS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFLAMMATION; LITERATURE; LIVER TOXICITY; LYMPHOCYTOPENIA; NEPHROTOXICITY; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PSORIASIS; PUVA; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SIDE EFFECT; SMOKING; THROMBOCYTE; THROMBOCYTE ADHESION;

CARDIOVASCULAR DISEASES; HUMANS; PSORIASIS; RISK FACTORS;

EID: 33845465632     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.07.011     Document Type: Review

References (78)

1. Krueger G., and Ellis C.N. Psoriasis-recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol 53 (2005) S94-S100
2. Chaturvedi V., Qin J.Z., Denning M.F., et al. Apoptosis in proliferating, senescent, and immortalized keratinocytes. J Biol Chem 274 (1999) 23358-23367
3. Roman M.J., Moeller E., Davis A., et al. Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med 144 (2006) 249-256
4. Dessein P.H., Joffe B.I., Veller M.G., et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol 32 (2005) 435-442
5. Horai R., Saijo S., Tanioka H., et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 191 (2000) 313-320
6. Shepherd J., Little M.C., and Nicklin M.J. Psoriasis-like cutaneous inflammation in mice lacking interleukin-1 receptor antagonist. J Invest Dermatol 122 (2004) 665-669
7. Mallbris L., Akre O., Granath F., et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 19 (2004) 225-230
8. Stern R.S., and Lange R. Cardiovascular disease, cancer, and cause of death in patients with psoriasis: 10 years prospective experience in a cohort of 1,380 patients. J Invest Dermatol 91 (1988) 197-201
9. McDonald C.J. Cardiovascular disease in psoriasis. J Invest Dermatol 92 (1989) 646-647
10. Henseler T., and Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 32 (1995) 982-986
11. Wong K., Gladman D.D., Husted J., Long J.A., and Farewell V.T. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 40 (1997) 1868-1872
12. Shbeeb M., Uramoto K.M., Gibson L.E., O'Fallon W.M., and Gabriel S.E. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol 27 (2000) 1247-1250
13. Gladman D.D., Farewell V.T., Wong K., and Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 41 (1998) 1103-1110
14. Brandrup F., Holm N., Grunnet N., Henningsen K., and Hansen H.E. Psoriasis in monozygotic twins: variations in expression in individuals with identical genetic constitution. Acta Derm Venereol 62 (1982) 229-236
15. Duffy D.L., Spelman L.S., and Martin N.G. Psoriasis in Australian twins. J Am Acad Dermatol 29 (1993) 428-434
16. Trembath R.C., Clough R.L., Rosbotham J.L., et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 6 (1997) 813-820
17. Helms C., Saccone N.L., Cao L., et al. Localization of PSORS1 to a haplotype block harboring HLA-C and distinct from corneodesmosin and HCR. Hum Genet 118 (2005) 466-476
18. Gudjonsson J.E., Karason A., Runarsdottir E.H., et al. Distinct clinical differences between HLA-Cw*0602 positive and negative psoriasis patients-an analysis of 1019 HLA-C- and HLA-B-typed patients. J Invest Dermatol 126 (2006) 740-745
19. Prens E.P., Benne K., van Damme J., et al. Interleukin-1 and interleukin-6 in psoriasis. J Invest Dermatol 95 (1990) 121S-124S
20. Schottelius A.J., Moldawer L.L., Dinarello C.A., et al. Biology of tumor necrosis factor-alpha implications for psoriasis. Exp Dermatol 13 (2004) 193-222
21. Torre-Amione G., Kapadia S., Lee J., et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 93 (1996) 704-711
22. Kubota T., McTiernan C.F., Frye C.S., et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 81 (1997) 627-635
23. Campalani E., Allen M.H., Fairhurst D., et al. Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. Br J Dermatol 154 (2006) 345-352
24. Eichner J.E., Dunn S.T., Perveen G., et al. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 155 (2002) 487-495
25. Yamauchi P.S., Rizk D., Kormeili T., Patnaik R., and Lowe N.J. Current systemic therapies for psoriasis: where are we now?. J Am Acad Dermatol 49 (2003) S66-S77
26. Dierkes J., and Westphal S. Effect of drugs on homocysteine concentrations. Semin Vasc Med 5 (2005) 124-139
27. van Ede A.E., Laan R.F., Rood M.J., et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 44 (2001) 1515-1524
28. Lebwohl M. A clinician's paradigm in the treatment of psoriasis. J Am Acad Dermatol 53 (2005) S59-S69
29. Griffiths C.E., Dubertret L., Ellis C.N., et al. Ciclosporin in psoriasis clinical practice: an international consensus statement. Br J Dermatol 150 Suppl. 67 (2004) 11-23
30. Katz H.I., Waalen J., and Leach E.E. Acitretin in psoriasis: an overview of adverse effects. J Am Acad Dermatol 41 (1999) S7-S12
31. de Jong R., Bezemer A.C., Zomerdijk T.P., et al. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol 26 (1996) 2067-2074
32. Hoefnagel J.J., Thio H.B., Willemze R., and Bouwes Bavinck J.N. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol 149 (2003) 363-369
33. Mrowietz U., Christophers E., and Altmeyer P. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study. Br J Dermatol 138 (1998) 456-460
34. Vis M., Nurmohamed M.T., Wolbink G., et al. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 32 (2005) 252-255
35. Irace C., Mancuso G., Fiaschi E., et al. Effect of anti TNFalpha therapy on arterial diameter and wall shear stress and HDL cholesterol. Atherosclerosis 177 (2004) 113-118
36. Rocha-Pereira P., Santos-Silva A., Rebelo I., et al. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 303 (2001) 33-39
37. Reynoso-von Drateln C., Martinez-Abundis E., Balcazar-Munoz B.R., Bustos-Saldana R., and Gonzalez-Ortiz M. Lipid profile, insulin secretion, and insulin sensitivity in psoriasis. J Am Acad Dermatol 48 (2003) 882-885
38. Lindegard B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 172 (1986) 298-304
39. Inerot A., Enerback C., Enlund F., et al. Collecting a set of psoriasis family material through a patient organisation; clinical characterisation and presence of additional disorders. BMC Dermatol 5 (2005) 10
40. Bonifati C., Mussi A., Carducci M., et al. Endothelin-1 levels are increased in sera and lesional skin extracts of psoriatic patients and correlate with disease severity. Acta Derm Venereol 78 (1998) 22-26
41. Sowers J.R. Hypertension, angiotensin II, and oxidative stress. N Engl J Med 346 (2002) 1999-2001
42. Ho V.C. The use of ciclosporin in psoriasis: a clinical review. Br J Dermatol 150 Suppl. 67 (2004) 1-10
43. Naldi L., Chatenoud L., Linder D., et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 125 (2005) 61-67
44. Rucevic I., Perl A., Barisic-Drusko V., and Adam-Perl M. The role of the low energy diet in psoriasis vulgaris treatment. Coll Antropol 27 Suppl. 1 (2003) 41-48
45. Wellen K.E., and Hotamisligil G.S. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 112 (2003) 1785-1788
46. Panagiotakos D.B., Pitsavos C., Yannakoulia M., Chrysohoou C., and Stefanadis C. The implication of obesity and central fat on markers of chronic inflammation: the ATTICA study. Atherosclerosis 183 (2005) 308-315
47. Weisberg S.P., McCann D., Desai M., et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112 (2003) 1796-1808
48. James W.P.T., Jackson-Leach R., Ni Mhurchu C., et al. Overweight and obesity (high body mass index). In: Ezzati M., Lopez A.D., Rodgers A., and Murray C.J.L. (Eds). Comparative quantification of health risks: global and regional burden of disease attributable to selected major risk factors vol. 1 (2004), WHO, Geneva 497-596
49. Kannel W.B., McGee D., and Gordon T. A general cardiovascular risk profile: the Framingham Study. Am J Cardiol 38 (1976) 46-51
50. Hotamisligil G.S., Peraldi P., Budavari A., et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271 (1996) 665-668
51. Paolisso G., Valentini G., Giugliano D., et al. Evidence for peripheral impaired glucose handling in patients with connective tissue diseases. Metabolism 40 (1991) 902-907
52. Binazzi M., Calandra P., and Lisi P. Statistical association between psoriasis and diabetes: further results. Arch Dermatol Res 254 (1975) 43-48
53. Herron M.D., Hinckley M., Hoffman M.S., et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 141 (2005) 1527-1534
54. Fortes C., Mastroeni S., Leffondre K., et al. Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol 141 (2005) 1580-1584
55. Ryder M.I., Saghizadeh M., Ding Y., Nguyen N., and Soskolne A. Effects of tobacco smoke on the secretion of interleukin-1beta, tumor necrosis factor-alpha, and transforming growth factor-beta from peripheral blood mononuclear cells. Oral Microbiol Immunol 17 (2002) 331-336
56. Okubo Y., and Koga M. Peripheral blood monocytes in psoriatic patients overproduce cytokines. J Dermatol Sci 17 (1998) 223-232
57. Flisiak I., Chodynicka B., Porebski P., and Flisiak R. Association between psoriasis severity and transforming growth factor beta(1) and beta (2) in plasma and scales from psoriatic lesions. Cytokine 19 (2002) 121-125
58. Aicher A., Heeschen C., Mohaupt M., et al. Nicotine strongly activates dendritic cell-mediated adaptive immunity: potential role for progression of atherosclerotic lesions. Circulation 107 (2003) 604-611
59. Briganti S., and Picardo M. Antioxidant activity, lipid peroxidation and skin diseases. What's new. J Eur Acad Dermatol Venereol 17 (2003) 663-669
60. Madamanchi N.R., Hakim Z.S., and Runge M.S. Oxidative stress in atherogenesis and arterial thrombosis: the disconnect between cellular studies and clinical outcomes. J Thromb Haemost 3 (2005) 254-267
61. Rocha-Pereira P., Santos-Silva A., Rebelo I., et al. The inflammatory response in mild and in severe psoriasis. Br J Dermatol 150 (2004) 917-928
62. Clarke R., and Lewington S. Homocysteine and coronary heart disease. Semin Vasc Med 2 (2002) 391-399
63. Vanizor Kural B., Orem A., Cimsit G., et al. Plasma homocysteine and its relationships with atherothrombotic markers in psoriatic patients. Clin Chim Acta 332 (2003) 23-30
64. Blann A.D. Endothelial cell activation, injury, damage and dysfunction: separate entities or mutual terms?. Blood Coagul Fibrinolysis 11 (2000) 623-630
65. Vita J.A., and Keaney Jr. J.F. Endothelial function: a barometer for cardiovascular risk?. Circulation 106 (2002) 640-642
66. Blann A.D., and Lip G.Y. The endothelium in atherothrombotic disease: assessment of function, mechanisms and clinical implications. Blood Coagul Fibrinolysis 9 (1998) 297-306
67. Boneu B., Abbal M., Plante J., and Bierme R. Letter: factor-VIII complex and endothelial damage. Lancet 1 (1975) 1430
68. Corretti M.C., Anderson T.J., Benjamin E.J., et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39 (2002) 257-265
69. Berrettini M., Parise P., Constantini V., Grasselli S., and Nenci G.G. Platelet activation in psoriasis. Thromb Haemost 53 (1985) 195-197
70. Vila L., Cullare C., Sola J., et al. Cyclooxygenase activity is increased in platelets from psoriatic patients. J Invest Dermatol 97 (1991) 922-926
71. Gawaz M., Langer H., and May A.E. Platelets in inflammation and atherogenesis. J Clin Invest 115 (2005) 3378-3384
72. Laufs U., La Fata V., Plutzky J., and Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97 (1998) 1129-1135
73. Kwak B., Mulhaupt F., Myit S., and Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 6 (2000) 1399-1402
74. Neuhaus O., Stuve O., Zamvil S.S., and Hartung H.P. Are statins a treatment option for multiple sclerosis?. Lancet Neurol 3 (2004) 369-371
75. Youssef S., Stuve O., Patarroyo J.C., et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420 (2002) 78-84
76. Hakamada-Taguchi R., Uehara Y., Kuribayashi K., et al. Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ Res 93 (2003) 948-956
77. Choi H.K., Hernan M.A., Seeger J.D., Robins J.M., and Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359 (2002) 1173-1177
78. Pearson T.A., Blair S.N., Daniels S.R., et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 Update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 106 (2002) 388-391